Guzman y Gomez Limited (ASX:GYG) Responds to ASX Compliance Inquiry on Half-Year Earnings
Guzman y Gomez Limited (ASX:GYG) confirms its half-year earnings aligned with market expectations in response to ASX compliance inquiry.
Tag: Regulatory News & Compliance
Biotron Limited (ASX:BIT) Withdraws Share Purchase Plan and Launches Rights Issue
Biotron Limited (ASX:BIT) withdraws its Share Purchase Plan and announces a $750,000 Rights Issue with Mahe Capital to secure its financial position.
Imricor Medical Systems (ASX:IMR) Submits Second FDA PMA Module
Imricor Medical Systems (ASX:IMR) submits its second FDA PMA module, advancing regulatory progress and preparing for upcoming product launches.
Kalina Power Limited (ASX:KPO) Addresses ASX’s Financial Queries
Kalina Power Limited (ASX:KPO) addresses ASX’s queries on its financial status, detailing ongoing fundraising efforts to sustain operations.
Jayride Group Limited (ASX:JAY) Launches Renounceable Entitlement Offer Amid Leadership Restructuring
Jayride Group (ASX:JAY) launches a renounceable entitlement offer to raise $4.3M and announces significant leadership changes.
New Age Exploration Limited (ASX:NAE) Requests Trading Halt
New Age Exploration Limited (ASX:NAE) requests a trading halt on the ASX pending a material capital raising announcement.
PainChek Limited (ASX:PCK) Releases Half Year Results
PainChek Limited (ASX:PCK) reports a 27% revenue increase in its half-year results, highlighting growth and expansion into the US market.
Neurotech International Ltd (ASX:NTI) Receives EMA Positive Opinion
Neurotech International Ltd (ASX:NTI) receives EMA positive opinion for NTI164 in Rett Syndrome, marking a key regulatory milestone.
Silk Logistics Holdings (ASX:SLH) Announces FY25 Half-Year Results and Acquisition Scheme
Silk Logistics (ASX:SLH) reports FY25 half-year financial results and announces an acquisition scheme with DP World Australia.
Telix Pharmaceuticals Limited (ASX:TLX) FDA Accepts BLA for TLX250-CDx
Telix Pharmaceuticals (ASX:TLX) announces FDA acceptance of BLA for TLX250-CDx, targeting kidney cancer imaging with a planned U.S. launch in 2025.